Morphotek, Inc. has entered into a license agreement with Centocor Ortho Biotech for the development and commercialization of an antibody targeting solid tumors. Financial terms were not disclosed. Morphotek has been granted an exclusive worldwide license for the development, manufacture and sale of the antibody. Preclinical studies conducted by Centocor have shown that the relevant antigen is over-expressed in many solid tumors. “We are delighted to conclude this license agreement w...